A Novel Balanced Dual Vasopressin V1a/V2 Receptor Antagonist for Treatment of Congestive Heart Failure: Results From a First-in-Man Study

被引：0
|
作者：
Pimenta, Eduardo
Jensen, Markus
Jung, David
Lobmeyer, Maximilian
Schmitt, Walter
Schaumann, Frank
Boxnick, Stefanie
Truebel, Hubert
机构：
来源：
CIRCULATION | 2017年 / 136卷
关键词：
Heart failure; Vasopressins; Abdominal aortic aneurysm;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
15196
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Bridged bicyclic vasopressin receptor antagonists V2-selective or dual V1a/V2 activity
    Dyatkin, AB
    Hoekstra, WJ
    Hlasta, DJ
    Andrade-Gordon, P
    de Garavilla, L
    Demarest, KT
    Gunnet, JW
    Hagemann, W
    Look, R
    Maryanoff, BE
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (21) : 3081 - 3084
  • [22] Tolvaptan.: Treatment of heart failure, vasopressin V2 antagonist.
    Sorbera, LA
    Castañer, J
    Bayés, M
    Silvestre, J
    DRUGS OF THE FUTURE, 2002, 27 (04) : 350 - 357
  • [23] Vascular Effects of RWJ-676070, a Selective Combined V1a/V2 Vasopressin Receptor Antagonist
    Coltamai, L.
    Bucher, M.
    Maillard, M. P.
    Shukla, U.
    Bohidar, N.
    Haskell, L.
    Bertelsen, K.
    Fedgchin, M.
    Vogt, B.
    Burnier, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (02) : 145 - 148
  • [24] Pharmacotherapy for hyponatraemia in heart failure: effects of a new combined vasopressin V1A/V2 receptor antagonist, conivaptan (YM087) administered orally
    Abraham, W
    Suresh, DP
    Wagoner, LE
    Haas, GJ
    Nelson, C
    Bakker-Arkema, RG
    EUROPEAN HEART JOURNAL, 2000, 21 : 345 - 345
  • [25] A novel vasopressin dual V1A/V2 receptor antagonist, conivaptan hydrochloride, improves hyponatremia in rats with syndrome of inappropriate secretion of antidiuretic hormone (SIADH)
    Wada, Koh-ichi
    Matsuyawa, Utane
    Fujimori, Akira
    Arai, Yukinori
    Sudoh, Katsumi
    Sasamata, Masao
    Miyata, Keiji
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2007, 30 (01) : 91 - 95
  • [26] The best of two worlds: Vascular protection and decongestion without RAAS stimulation mediated by a novel dual acting V1a/V2 vasopressin receptor antagonist
    Kolkhof, P.
    Dinh, W.
    Mondritzki, T.
    Pook, E.
    Schmeck, C.
    Hueser, J.
    EUROPEAN HEART JOURNAL, 2018, 39 : 251 - 251
  • [27] Efficacy of the vasopressin V1A/V2 antagonist conivaptan in patients with euvolemic or hypervolemic hyponatremia
    Ghali, JK
    Bisaha, JG
    Smith, N
    CIRCULATION, 2004, 110 (17) : 723 - 723
  • [28] Next-generation spirobenzazepines:: Identification of RWJ-676070 as a balanced vasopressin V1a/V2 receptor antagonist for human clinical studies
    Xiang, Min Amy
    Rybczynski, Philip J.
    Patel, Mona
    Chen, Robert H.
    McComsey, David F.
    Zhang, Han-Cheng
    Gunnet, Joseph W.
    Look, Richard
    Wang, Yuanping
    Minor, Lisa K.
    Zhong, H. Marlon
    Villani, Frank J.
    Demarest, Keith T.
    Damiano, Bruce P.
    Maryanoff, Bruce E.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (23) : 6623 - 6628
  • [29] Mapping peptide antagonist binding sites of the human V1a and V2 vasopressin receptors
    Mouillac, B
    Phalipou, S
    Cotte, N
    Balestre, MN
    Hibert, M
    Manning, M
    Barberis, C
    VASOPRESSIN AND OXYTOCIN: MOLECULAR, CELLULAR, AND CLINICAL ADVANCES, 1998, 449 : 359 - 361
  • [30] Downregulation of vasopressin V2 receptor promoter activity via V1a receptor pathway
    Izumi, Yuichiro
    Nakayama, Yushi
    Mori, Tomohiko
    Miyazaki, Hiroki
    Inoue, Hideki
    Kohda, Yukimasa
    Inoue, Takeaki
    Nonoguchi, Hiroshi
    Tomita, Kimio
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2007, 292 (05) : F1418 - F1426
12345